16 February 2018 - - Results from the randomized phase II CONDOR trial were presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium co-sponsored by the Arlington, Virginia-based radiation oncology society American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), and the American Head and Neck Society, ASTRO said.
Analysis of the phase II CONDOR trial indicate that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic head and neck cancer and has the potential to slow growth in tumors with low or negative expression of the PD-L1 protein.
No difference in clinical activity was observed between durvalumab alone or in combination with tremelimumab.
Findings are based on 267 patients with metastatic or recurrent cancer of the oral cavity, oropharynx, hypopharynx, or larynx who had not responded to prior platinum-based chemotherapy, and who had low or negative expression of the PD-L1 protein.
The 2-day 2018 Multidisciplinary Head and Neck Cancer Symposium, held in Scottsdale, Arizona, includes interactive educational sessions focused on topics such as novel multidisciplinary therapies, directed therapy, treatment guidelines, prevention, surveillance and supportive care, as well as oral abstract presentations of the current science of relevance to the head and neck cancer community.
ASTRO radiation oncology society represents more than 10,000 physicians, nurses, biologists, physicists, radiation therapists, dosimetrists, and other health care professionals who specialize in treating patients with radiation therapies.
The society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy.